I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Richard Koo Biography and Net Worth

Director of Amphastar Pharmaceuticals

Richard Koo, C.P.A. has served as a member of our Board of Directors since 2003. For over thirty years, Mr. Koo has been the managing partner of Koo, Chow and Company, Certified Public Accountants, and also serves as CEO and President of K.C. Group International Inc. and a Director of EverTrust Bank. Mr. Koo has extensive experience as a CPA in auditing and taxation and has worked with PricewaterhouseCoopers LLP in various public offering audit assignments. He has worked as a finance and taxation expert for the United Nations and has written numerous books and publications. Mr. Koo received a B.S. in Management from the National Taiwan University and an M.B.A. in Accounting from San Jose State University.

What is Richard Koo's net worth?: The estimated net worth of Richard Koo is at least $10.92 million as of June 1st, 2021. Mr. Koo owns 279,097 shares of Amphastar Pharmaceuticals stock worth more than $10,923,857 as of December 22nd. This net worth estimate does not reflect any other assets that Mr. Koo may own. Learn More about Richard Koo's net worth.
How do I contact Richard Koo?: The corporate mailing address for Mr. Koo and other Amphastar Pharmaceuticals executives is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. Amphastar Pharmaceuticals can also be reached via phone at (909) 980-9484 and via email at [email protected]. Learn More on Richard Koo's contact information.
Has Richard Koo been buying or selling shares of Amphastar Pharmaceuticals?: Richard Koo has not been actively trading shares of Amphastar Pharmaceuticals during the past quarter. Most recently, Richard Koo sold 25,827 shares of the business's stock in a transaction on Tuesday, June 1st. The shares were sold at an average price of $19.28, for a transaction totalling $497,944.56. Following the completion of the sale, the director now directly owns 279,097 shares of the company's stock, valued at $5,380,990.16. Learn More on Richard Koo's trading history.
Who are Amphastar Pharmaceuticals' active insiders?: Amphastar Pharmaceuticals' insider roster includes Diane Gerst (Director), Richard Koo (Director), Howard Lee (Director), Yakob Liawatidewi (EVP), Mary Luo (COO), Ziping Luo (Chairman), William Peters (CFO), Floyd Petersen (Director), Richard Prins (Director), Michael Zasloff (Director), Jack Zhang (CEO), Yongfeng Zhang (Co-Founder), and Rong Zhou (EVP). Learn More on Amphastar Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Amphastar Pharmaceuticals?: In the last year, insiders at the sold shares 21 times. They sold a total of 363,042 shares worth more than $19,564,696.71. The most recent insider tranaction occured on December, 12th when EVP Rong Zhou sold 7,000 shares worth more than $310,940.00. Insiders at Amphastar Pharmaceuticals own 27.1% of the company. Learn More about insider trades at Amphastar Pharmaceuticals.
Information on this page was last updated on 12/12/2024.

Richard Koo Insider Trading History at Amphastar Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/1/2021	Sell	25,827	$19.28	$497,944.56	279,097
5/27/2020	Sell	47,782	$18.18	$868,676.76	295,201
12/11/2018	Sell	29,278	$21.32	$624,206.96	89,263

Richard Koo Buying and Selling Activity at Amphastar Pharmaceuticals

Amphastar Pharmaceuticals Company Overview

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Today's Range

Now: $39.14

$38.96

$40.74

50 Day Range

MA: $46.46

$39.14

$53.40

2 Week Range

Now: $39.14

$36.56

$65.92

Volume

2,483,214 shs

Average Volume

415,267 shs

Market Capitalization

$1.88 billion

P/E Ratio

13.05

Dividend Yield

N/A

Beta

0.78

I was wrong. Dead wrong.

From Porter & Company | Ad